NovaBridge Biosciences (NBP) Long-Term Deferred Tax (2018 - 2022)

NovaBridge Biosciences (NBP) has reported Long-Term Deferred Tax for 3 consecutive years, with $111.4 million the latest figure, recorded in Q4 2022.

• In Q4 2022, Long-Term Deferred Tax rose 87.16% year-over-year to $111.4 million; the TTM figure through Dec 2022 stood at $111.4 million (up 87.16% YoY), while the FY2022 annual figure was $114.9 million, up 92.99% from the prior year.
• Long-Term Deferred Tax climbed to $111.4 million in Q4 2022 per NBP's latest filing, from $59.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $111.4 million in Q4 2022 and bottomed at $13.3 million in Q4 2018.
• Historically, Long-Term Deferred Tax has averaged $61.4 million across 3 years, with a median of $59.5 million in 2021.
• On a YoY basis, Long-Term Deferred Tax climbed as much as 87.16% in 2022 and fell as far as 87.16% in 2022.
• NovaBridge Biosciences' Long-Term Deferred Tax stood at $13.3 million in 2018, then jumped by 346.6% to $59.5 million in 2021, then jumped by 87.16% to $111.4 million in 2022.
• Business Quant data shows NBP's Long-Term Deferred Tax at $111.4 million in Q4 2022, $59.5 million in Q4 2021, and $13.3 million in Q4 2018.